indinavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 1437 150378-17-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • indinavir
  • indinavir sulphate
  • crixivan
  • indinavir sulfate
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
  • Molecular weight: 613.80
  • Formula: C36H47N5O4
  • CLOGP: 3.68
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 118.03
  • ALOGS: -4.11
  • ROTB: 12
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 27.21 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.82 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.36 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 13, 1996 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Viral mutation identified 205.68 54.05 32 652 1778 63486560
Drug resistance 139.52 54.05 35 649 22898 63465440
Virologic failure 84.44 54.05 15 669 1847 63486491
Pathogen resistance 76.91 54.05 17 667 6381 63481957

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 914.30 42.68 164 2313 3180 34951274
Mitochondrial toxicity 774.34 42.68 138 2339 2561 34951893
Eyelid ptosis 669.79 42.68 138 2339 5628 34948826
Diplopia 517.80 42.68 137 2340 16706 34937748
Progressive external ophthalmoplegia 434.80 42.68 77 2400 1358 34953096
Ophthalmoplegia 155.53 42.68 34 2443 1806 34952648
Virologic failure 129.05 42.68 33 2444 3447 34951007
Blood lactic acid increased 111.79 42.68 34 2443 6694 34947760
Dysphagia 101.54 42.68 60 2417 62321 34892133
Pathogen resistance 100.31 42.68 34 2443 9448 34945006
Viral mutation identified 99.72 42.68 26 2451 2928 34951526
Hypertriglyceridaemia 76.58 42.68 27 2450 8421 34946033
Lipoatrophy 75.48 42.68 15 2462 496 34953958
Multiple-drug resistance 72.38 42.68 23 2454 5216 34949238
Dyslipidaemia 53.20 42.68 20 2457 7468 34946986
Mitochondrial myopathy 48.89 42.68 9 2468 196 34954258
Nephrolithiasis 48.76 42.68 29 2448 30304 34924150
Drug resistance 47.53 42.68 27 2450 25900 34928554
Foetal exposure during pregnancy 47.53 42.68 31 2446 38070 34916384
Pinealoblastoma 43.17 42.68 8 2469 181 34954273

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 975.88 42.36 162 2581 4163 79737482
Mitochondrial toxicity 846.66 42.36 137 2606 2977 79738668
Eyelid ptosis 673.48 42.36 137 2606 10907 79730738
Diplopia 517.50 42.36 136 2607 33330 79708315
Progressive external ophthalmoplegia 489.74 42.36 77 2666 1368 79740277
Viral mutation identified 241.23 42.36 49 2694 3809 79737836
Virologic failure 163.11 42.36 36 2707 4155 79737490
Ophthalmoplegia 158.61 42.36 33 2710 2879 79738766
Drug resistance 154.21 42.36 57 2686 42156 79699489
Pathogen resistance 127.83 42.36 38 2705 14304 79727341
Multiple-drug resistance 108.32 42.36 30 2713 8778 79732867
Dysphagia 104.31 42.36 60 2683 122076 79619569
Lipoatrophy 94.86 42.36 17 2726 672 79740973
Nephrolithiasis 88.53 42.36 41 2702 53250 79688395
Dyslipidaemia 74.76 42.36 24 2719 11609 79730036
Blood lactic acid increased 64.67 42.36 22 2721 12722 79728923
Immune reconstitution inflammatory syndrome 59.07 42.36 21 2722 13820 79727825
Mitochondrial myopathy 52.05 42.36 9 2734 288 79741357
Osteonecrosis 51.82 42.36 24 2719 31071 79710574
Pinealoblastoma 48.54 42.36 7 2736 66 79741579

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
CHEBI has role CHEBI:35660 HIV protease inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D000084762 Viral Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Pyuria contraindication 4800001 DOID:1439
Hypercholesterolemia contraindication 13644009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Cirrhosis of liver contraindication 19943007 DOID:5082
Blood in urine contraindication 34436003
Hemolytic anemia contraindication 61261009 DOID:583
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Hemophilia contraindication 90935002
Kidney stone contraindication 95570007
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Hypertriglyceridemia contraindication 302870006
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.82 acidic
pKa2 12.01 acidic
pKa3 6.96 Basic
pKa4 3.56 Basic
pKa5 2.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thromboxane-A synthase Enzyme IC50 5.73 DRUG MATRIX
Substance-K receptor GPCR Ki 5.77 DRUG MATRIX
Multidrug and toxin extrusion protein 1 Transporter IC50 5.77 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 5.11 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 6.40 DRUG MATRIX
Pol polyprotein Enzyme INHIBITOR Ki 10.15 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 9.22 WOMBAT-PK
Protease Enzyme Ki 8.48 CHEMBL
Protease Enzyme Ki 9.27 CHEMBL
Protease Unclassified Ki 9.06 CHEMBL
Protease Unclassified Ki 9.42 CHEMBL

External reference:

IDSource
4024026 VUID
N0000022031 NUI
D00897 KEGG_DRUG
157810-81-6 SECONDARY_CAS_RN
4020965 VANDF
4024026 VANDF
C0376637 UMLSCUI
CHEBI:44032 CHEBI
MK1 PDB_CHEM_ID
CHEMBL115 ChEMBL_ID
CHEMBL1735 ChEMBL_ID
D019469 MESH_DESCRIPTOR_UI
DB00224 DRUGBANK_ID
12684 IUPHAR_LIGAND_ID
5W6YA9PKKH UNII
5362440 PUBCHEM_CID
114289 RXNORM
4875 MMSL
6513 MMSL
d03985 MMSL
005733 NDDF
005734 NDDF
108695003 SNOMEDCT_US
108696002 SNOMEDCT_US
372529006 SNOMEDCT_US
180683-37-8 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 0006-0570 CAPSULE 100 mg ORAL NDA 28 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 0006-0571 CAPSULE 200 mg ORAL NDA 28 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 0006-0573 CAPSULE 400 mg ORAL NDA 28 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-064 CAPSULE 400 mg ORAL NDA 28 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 21695-366 CAPSULE 400 mg ORAL NDA 27 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 53808-0661 CAPSULE 400 mg ORAL NDA 27 sections